TidalSense

Investor: Cross-Border Impact Ventures

Cambridge-based health tech startup TidalSense has successfully raised £14.2 million (equivalent to $19 million) in a recent funding round. This capital injection is earmarked to accelerate the commercial expansion of its innovative AI-powered respiratory diagnostic device, N-Tidal Diagnose, and to prepare for entry into the US market.Summary of transaction details:Value: £14.2 million ($19 million)Sector: Healthcare & Biotech (AI Diagnostics)Advisor: Not mentionedKey Entities: TidalSense (Target), Cross-Border Impact Ventures (Lead Investor), BGF, Airstream Capital, Foresight Group (Returning Backers)Location: Cambridge, UK (Target)Note: This funding round highlights a strategic investment in advanced AI diagnostics to address significant gaps in respiratory disease diagnosis. By supporting TidalSense's expansion, investors aim to improve access to accurate, rapid diagnostic tools for conditions like COPD globally, particularly benefiting underserved communities.

Investor: Cross Border Impact Ventures

TidalSense, a Cambridge-based start-up, has successfully secured £14.2 million in a significant funding round to commercialise its innovative handheld device for rapid lung disease diagnosis.Summary of transaction details:Value: £14.2 millionSector: Healthcare & BiotechAdvisor: Not specifiedKey Entities: TidalSense (Target), Cross Border Impact Ventures (Lead Investor), BGF, Airstream Capital, Foresight Group (Returning Backers)Location: Cambridge, UK (Target)Note: This funding round will enable TidalSense to expand the rollout of its AI-powered diagnostic test across the NHS, pursue commercial opportunities in Europe, and enter the US market, addressing the critical need for earlier and more efficient diagnosis of chronic obstructive pulmonary disease (COPD). The investment underscores a growing interest in defensible hardware-based solutions within the MedTech sector.

Investor: BGF, Downing Ventures